Taken together, the upregulation of CCL2 and GM-CSF in regrown tumors detected in our study suggests increased TIM infiltration and proliferation in relapsed tumors, an immunosuppressive shift in the tumor microenvironment, and enhanced glioma cell motility. The gene discussed is CCL2; the disease is central nervous system cancer.